The Effect of Patient Cost-Sharing on Antidepressant and Adjunctive Therapy Use

Otsuka Pharmaceutical Development & Commercialization, Inc.48,865 enrolled

Overview

The primary objective of this study is to measure the effects of patient cost-sharing on the initiation of adjunctive treatment and subsequent healthcare utilization and expenditures among a population of commercially insured adults on antidepressant therapy.

Study Type

OBSERVATIONAL

Enrollment

48,865

Conditions

Depressive Disorder, Major

Eligibility

Sex: ALLMin age: 18 YearsMax age: 64 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adult patients (aged 18-64) will be selected from the MarketScan Commercial Database between January 1, 2004, and September 30, 2008, if they have at least two medical claims with a diagnosis of depression and at least one prescription fill for an antidepressant medication. Exclusion Criteria: * Patients who have any claim with a diagnosis of dementia, schizophrenia, delusional disorder, psychoses, pervasive development disorder, mental retardation, cerebral degenerations, Parkinson's disease, senility, manic depression, bipolar disorder, or major depressive disorder with psychotic symptoms.

Outcomes

Primary Outcomes

The primary outcome is any use of adjunctive treatment (combined and by class) and the time to initiation of adjunctive treatment (combined and by class).

16 months of medical and prescription drug coverage after the initial antidepressant prescription claim

Time frame: 16 months

Secondary Outcomes

sensitivity to cost-sharing will be examined as a function of treatment resistance

16 months of medical and prescription drug coverage after the initial antidepressant prescription claim

Time frame: 16 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.